-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
It may soon be possible to distinguish the 4 constituent neural tube cell tumors (the most common malignant brain tumors in children) from
the more aggressive groups of 3 tumors.
Four-component neural tube cell tumors have been identified, with group 3 being the most aggressive, with a 5-year survival rate of 45% to 60%.
To date, it has been difficult to distinguish group 3 tumors (with a better prognosis (5-year survival rate of 75%-80%) from
group 4 tumors.
"Group 3 and group 4 constituent neural tube cell tumors are very similar and are difficult to distinguish
under the microscope.
In particular, the researchers looked at long non-coding RNAs (lncRNAs) that experts believe do not play a role
in the construction of proteins.
Perera and other researchers found that an lncRNA gene called SPRIGHTLY was highly expressed in 4 constituent neural tube cell tumors, but not in group 3
.
"Obviously, SPRIGHTLY can be used as a biomarker for group 4 because we haven't seen this in group 3 or two other groups
.
The researchers also conducted laboratory tests showing that SPRIGHTLY interacts with another protein called PTPB1, which regulates the production
of the SMYD3 protein.
Bongyong Lee, Keisuke Katsushima, Rudramani Pokhrel, Menglang Yuan, Stacie Stapleton, George Jallo, Robert J Wechsler-Reya, Charles G Eberhart, Animesh Ray, Ranjan J Perera.
